Biophysium
Cardiovascular healthCardiovascular health
Cardiovascular diseases are the leading cause of disability and premature death in the world. Consequently, these pathologies constitute a major public health problem. According to the WHO, in 2030 nearly 23.6 million people will die of cardiovascular disease per year and according to projections, these diseases will remain the first cause of mortality in front of cancers. Cardiovascular system disorders include a number of conditions that can impair myocardial morphology and function such as myocardial ischemia, valvular pathologies, heart failure, rhythm disorders, endothelial dysfunction, coronary artery disease, peripheral arterial disease and high blood pressure. The proper functioning of the cardiovascular system remains a major concern and development of innovative treatments to preserve it a priority.
Thus, reducing the frequency of clinical events and premature mortality in people with advanced cardiovascular pathology and in people whose risk is increased by the presence of one or more risk factors is a major objective. Biophysium’s competences allow you to evaluate cardiovascular dysfunctions which can be linked to a metabolic pathology (diabetes, obesity, metabolic syndrome, hyperglycemia, lipid oxidation, etc.), a clinical event such as a myocardial infarction or as the consequence of a toxic treatment.
We will also provide the tools to evaluate the potential effects of preventive or rehabilitation strategies such as medications, physical activity or nutritional interventions. Our expertise will allow us to assess specifically the generation of oxidative stress (cytosolic or mitochondrial), the nitric oxide pathway, inflammation as well as other biomarkers. Moreover, metabolomic and proteomic analyses will allow you to bring mechanistic elements to your proof of concept.
In order to meet your requirements, we are able to use different rodent models obtained by pharmacological interventions, diet modifications but also genetically modified models. The recording of basic physiological parameters (weight, food intake, behavior) is common to all our animal models.
Cell culture
Endothelial cells
Smooth muscle cells
Angiogenesis
Pre-clinical models
Arterial hypertension
In vivo or ex vivo myocardial ischemia
Heart failure
Cardiac fatigue
Dyslipidemia and Atherosclerosis
ApoE-/- or KO mice for LDL receptor
Hypercholesterolemia
Obesity
(High Fat diet, ob/ob rat and db/db mouse)
Type 1 or 2 Diabetes
(Zucker or Goto-Kakizaki rat, DT-1 – streptozotocine)
Acute hyperglycemia
Hyperlipidemia
Voluntary or imposed exercise
(wheel and treadmill)
Performance test
(MAS, VO2 max)
Customized diet adapted to your project
Any other genetic or induced rat or mouse model
Isolated cardiomyocyte
Oxydative stress production
Mitochondrial function
Calcium retention capacity, fusion, fission, swelling, oxidative stress
Samples : urine, feces, blood or tissue/organ
Product administration
Injection, gavage, drinking water, food
Pulmonary hypertension
Clinical models
Obese
Diabetic
Cardiovascular risk factors
Voluntary or imposed physical exercise
Microcirculatory function
Fitness and performance evaluation
Functional exploration
Human: high resolution echocardiography at rest or under stress conditions
(dobutamine, exercise, etc..)
Myocardial remodeling,ventricular or atrial myocardial deformations, twist and untwist mechanism, myocardial work
Heart rate variability
Physical test
gas exchange, VO2 max, MAS
Telemetry monitoring
Cardiac and vascular imaging by ultrasound
Systolic and diastolic function, regional myocardial deformation, cardiac and vascular morphology, cardiac and vascular remodeling
Microcirculatory function
Body composition
Urinary and blood biomarkers
Lipid and oxidized lipid profile (cholesterol and LDL), carbohydrate profile, inflammatory cytokines, metabolomic, oxidative stress, MicroRNA
Electrocardiogram
Isolated perfused heart model of Langendorff
Endothelial function
Arterial pressure by non-invasive plethysmography Tail cuff method
Millar probe : left ventricular presure and volume loops
Calcium transient and contractility
Technical plateform
Surgical procedure
Millar, transonic, myocardial ischemia, acute hyperglycemia
Glucose dans lipid homeostasis
Infarct size area by planimetry
Measurement of atheromatous plaque size by ultrasound, histology and colorimetry
Evaluation of atheromatous plaque characteristics (fibrosis, macrophage infiltration) by histology
Isolated vessel model and vasoreactivity test (aorta, coronary, pulmonary artery, femoral, intra-pulmonary)
Blood lipid profile
TG, HDL, LDL, cholesterol
oxydation
Cholesterol and LDL
Isolated cardiomyocyte and mitochondria
Oxidative stress and nitric oxide production, calcium retention cycle, immunofluorescence
Urinary, faecal, tissue and blood specific biomarkers
Biochemistery & translational approach
Biochemical tests
Western blot, ELISA kit, protein activity, S-nitrosoproteomic
Histology for characterization
Hematoxylin-eosin, Sirius Red, Oil-Red-O, Masson Trichome, PAS staining, right ventricle morphology, immunohistology at request
Confocal and fluorescent microscopy
Mitochondrial function
Calcium retention, fusion, fission, swelling
S-Nitrosylation, cytosolic and mitochondrial regulation of oxidative stress production
Metabolomic and proteomic through mass spectrometry
Evaluation of cardiac and vascular oxidative stress and inflammation
Complete blood analysis
Tissue lipid oxidation
Top
